Aclaris Therapeutics Inc., a clinical-stage biopharma innovator targeting immuno-inflammatory diseases, has announced promising topline results from its Phase 2a trial of ATI-2138.
This open-label, single-arm study evaluated the investigational oral therapy in 14 patients with moderate-to-severe atopic dermatitis (AD).
What Makes ATI-2138 Stand Out?
- Dual Inhibitor: ATI-2138 targets both ITK and JAK3, offering a novel mechanism for immune modulation.
- Low Dose, High Impact: Patients were treated with 10 mg BID for 12 weeks, showing clinically meaningful results.
- No Serious Adverse Events: Safety profile was clean—no SAEs or significant lab abnormalities.
Key Outcomes from the Trial
1. Confirmed Safety and Tolerability
- No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) were reported.
- Only four treatment-related adverse events (TRAEs) were observed across three patients—all were mild or moderate and resolved during treatment.
2. Clinically Meaningful Efficacy
- EASI Scores: Significant reductions in the Eczema Area and Severity Index.
- Itch Reduction: Multiple patients achieved ≥4-point improvement in worst itch (PP-NRS).
- Comparability: Results suggest comparable or better efficacy than approved JAK or IL-4/13 inhibitors, even at this low dose.
Why This Matters for Future Indications
The success of this trial validates Aclaris’ broader ITK-focused drug development strategy.
“We accomplished our goals: confirm tolerability, test the mechanism in AD, and validate ITK as a therapeutic target,”
- Dr. Neal Walker, CEO, Aclaris.
Given the strong results, Aclaris plans to advance ATI-2138 in alopecia areata, with potential to expand into vitiligo and other Th2/Th1/Th17-mediated diseases.
Leading Experts Weigh In
“The PD data are compelling. We saw strong downregulation of Th2, Th1/Th17, and fibrosis markers,”
- Dr. Emma Guttman, Professor of Dermatology & Immunology, Mount Sinai.
She emphasized the potential of ITK inhibition as a therapeutic strategy for autoimmune and atopic disorders.
About ATI-2138
Mechanism of Action:
- Inhibits ITK (regulator of T-cell receptor signaling)
- Inhibits JAK3 (partner to JAK1 in IL-2 receptor signaling)
Therapeutic Potential:
- Supports T cell modulation without the safety risks of broader JAK inhibition
- Demonstrated efficacy in animal models and healthy human SAD/MAD trials
What’s Next?
Aclaris plans to:
- Advance ATI-2138 into larger clinical trials for alopecia areata
- Explore additional autoimmune and inflammatory conditions linked to T-cell and IL-2Rγc signaling
Final Takeaway
ATI-2138 could redefine the treatment paradigm for atopic dermatitis and T-cell driven autoimmune diseases. Aclaris has cleared a major hurdle—now the real momentum begins.
